References
- 1. J. S. Au and P. J. Pockros, Novel therapeutic approaches for hepatitis C, Clin. Pharmacol. Ther. 95 (2014) 78–88; DOI: 10.1038/clpt.2013.206.
- 2. M. P. Manns, J. G. McHutchison, S. C. Gordon, V. K. Rustgi, M. Shiffman, R. Reindollar, Z. D. Goodman, K. Koury, M. Ling and J. K. Albrecht, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet358 (2001) 958–965.
- 3. M. W. Fried, M. L. Shiffman, K. R. Reddy, C. Smith, G. Marinos, F. L. Gonçales Jr., D. Häussinger, M. Diago, G. Carosi, D. Dhumeaux, A. Craxi, A. Lin, J. Hoffman and J. Yu, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N. Engl. J. Med.347 (2002) 975–982; DOI: 10.1056/NEJMoa020047.
- 4. Y. Bansal and O. Silakari, The therapeutic journey of benzimidazoles: A review, Bioorg. Med. Chem.20 (2012) 6208–6236; DOI: 10.1016/j.bmc.2012.09.013.
- 5. V. Boido, G. Paglietti, M. Tonelli and G. Vitale, Non-nucleoside Benzimidazoles as Antiviral Drugs Against HCV and RSV Infections, in RNA-Viruses. Enzymatic and Receptoral Inhibitors (Ed. A. Carta), Research Signpost, Kerala 2009, pp. 41–93.
- 6. B. A. Katz, J. Clark, J. Finer-Moore, T. Jenkins, C. Johnson, M. Ross, C. Luong, W. Moore and R. Stroud, Design of potent selective zinc-mediated serine protease inhibitors, Nature391 (1998) 608–612; DOI: 10.1038/35422.
- 7. D. Sperandio, A. R. Gangloff, J. Litvak, R. Goldsmith, J. M. Hataye, V. R. Wang, E. J. Shelton, K. Elrod, J. W. Janc, J. M. Clark, K. Rice, S. Weinheimer, K. Yeung, N. A. Meanwell, D. Hernandez, A. J. Staab, B. L. Venables and J. R. Spencer, Highly potent non-peptidic inhibitors of the HCV NS3/NS4A serine protease, Bioorg. Med. Chem. Lett.12 (2002) 3129–3133; DOI: 10.1016/S0960-894X(02)00680-7.
- 8. H. I. El Diwani, H. T. Abdel-Mohsen, I. Salama, F. A.-F. Ragab, M. M. Ramla, S. A. Galal, M. M. Abdalla, A. Abdel-Wahab and M. A. El Demellawy, Synthesis, molecular modeling, and biological evaluation of novel benzimidazole derivatives as inhibitors of hepatitis C virus RNA replication, Chem. Pharm. Bull.62 (2014) 856–866; DOI: 10.1248/cpb.c13-01009.
- 9. L. Garuti, M. Roberti and G. Gentilomi, Synthesis and antiviral assays of some 2-substituted benzimidazole-N-carbamates, Farmaco55 (2000) 35–39; DOI: 10.1016/S0014-827X(99)00117-2.
- 10. S. Budow, M. Kozlowska, A. Gorska, Z. Kazimierczuk, H. Eickmeier, P. La Colla, G. Gosselin and F. Seela, Substituted benzimidazole: antivral activity and synthesis of nucleosides, ARKIVOC iii (2009) 225–250; DOI: 10.3998/ark.5550190.0010.319.
- 11. M. F. Tonelli, F. Novelli, B. Tasso, I. Vazzana, A. Sparatore, V. Boido, F. Sparatore, P. La Colla, G. Sanna, G. Giliberti, B. Busonera, P. Farci, C. Ibba and R. Loddo, Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents, Bioorg. Med. Chem.22 (2014) 4893–4909; DOI: 10.1016/j.bmc.2014.06.043.
- 12. Y. Saito, V. Escuret, D. Durantel, F. Zoulim, R. F. Schinazic and L. A. Agrofoglio, Synthesis of 1,2,3-triazolo-carbanucleoside analogues of ribavirin targeting an HCV in replicon, Bioorg. Med. Chem.11 (2003) 3633–3639; DOI: 10.1016/S0968-0896(03)00349-3.
- 13. F. D. Da Silva, M. C. B. V. de Souza, I. I. P. Frugulhetti, H. C. Castro, S. L. D Souza, T. M. L. de Souza, D. Q. Rodrigues, A. M. T. Souza, P. A. Abreu, F. Passamani, C. R. Rodrigues and V. F. Ferreira, Synthesis, HIV-RT inhibitory activity and SAR of 1-benzyl-1H-1,2,3-triazole derivatives of carbohydrates, Eur. J. Med. Chem.44 (2009) 373–383; DOI: 10.1016/j.ejmech.2008.02.047.
- 14. D. K. Mohapatra, P. K. Maity, M. Shabab and M. I. Khan, Click chemistry based rapid one-pot synthesis and evaluation for protease inhibition of new tetracyclic triazole fused benzodiazepine derivatives, Bioorg. Med. Chem.19 (2009) 5241–5245; DOI: 10.1016/j.bmcl.2009.06.107.
- 15. T. O. Olomola, R. Klein, K. A. Lobb, Y. Sayed and P. T. Kaye, Synthesis and evaluation of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase inhibitors, Bioorg. Med. Chem.21 (2013) 1964–1971; DOI: 10.1016/j.bmc.2013.01.025.
- 16. M. M. Heravi, A. Keivanloo, M. Rahimizadeh, M. Bakavoli and M. Ghassemzadeh, Pd–Cu catalyzed heterocyclization during Sonogashira coupling: synthesis of 3-benzylthiazolo[3,2-a]benzimidazole, Tetrahedron Lett.45 (2004) 5747–5749; DOI: 10.1016/j.tetlet.2004.05.094.
- 17. K.-C. Tiew, D. Dou, T. Teramoto, H. Lai, K. R. Alliston, G. H. Lushington, R. Padmanabhan and W. C. Groutas, Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d] isothiazol-3(2H)-one derivatives, Bioorg. Med. Chem.20 (2012) 1213–1221; DOI: 10.1016/j.bmc.2011.12.047.
- 18. C. Baba, K. Yanagida, T. Kanzaki and M. Baba, Colorimetric lactate dehydrogenase (LDH) assay for evaluation of antiviral activity against bovine viral diarrhoea virus (BVDV) in vitro, Antivir. Chem. Chemother.16 (2005) 33–39; DOI: 10.1016/j.biomaterials.2014.01.054.
- 19. K. Sako, H. Aoyama, S. Sato, Y. Hashimoto and M. Baba, γ-carboline derivatives with anti-bovine viral diarrhea virus (BVDV) activity, Bioorg. Med. Chem.16 (2008) 3780–3790; DOI: 10.1016/j.bmc.2008.01.052.
- 20. H. C. Kolb, M. G. Finn and K. B. Sharpless, Click chemistry: Diverse chemical function from a few good reactions, Angew. Chem. Int. Ed.40 (2001) 2004–2021; DOI: 10.1002/1521-3773(20010601)40:11<;2004::AID-ANIE2004>3.0.CO;2-5.
- 21. J. E. Moses and A. D. Moorhouse, The growing applications of click chemistry, Chem. Soc. Rev.36 (2007) 1249–1262; DOI: 10.1039/b613014n.
- 22. S. G. Agalave, S. R. Maujan and V. S. Pore, Click chemistry: 1,2,3-Triazoles as pharmacophores, Chem. Asian J.6 (2011) 2696–2718; DOI: 10.1002/asia.201100432.
- 23. J.-F. Lutz and Z. Zarafshani, Efficient construction of therapeutics, bioconjugates, biomaterials and bioactive surfaces using azide-alkyne “click” chemistry, Adv. Drug Deliv. Rev.60 (2008) 958–970; DOI: 10.1016/j.addr.2008.02.004.
- 24. K. Lin, R. B. Perni, A. D. Kwong and c. Lin, VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells, Antimicrob. Agents. Cli.50 (2006) 1813–1822; DOI: 10.1128/AAC.50.5.1813-1822.2006.
- 25. J. G. Topliss, Utilization of operational schemes for analog synthesis in drug design, J. Med. Chem.15 (1972) 1006–1011; DOI: 10.1021/jm00280a002.
- 26. J. G. Topliss, A manual method for applying the Hansch approach to drug design, J. Med. Chem.20 (1977) 463–469; DOI: 10.1021/jm00214a001.